Multifunctional anti-angiogenic activity of the cyclic peroxide ANO-2 with antitumor activity

International Journal of Cancer

Volumn 100, Issue 2, 2002, Pages 220-227

  Arakawa, Kazuhito ^a   Endo, Yoshio ^a   Kimura, Masashi ^a   Yoshida, Takanori ^a   Kitaoka, Takeshi ^a   Inakazu, Tomoyasu ^b   Nonami, Yuji ^b   Abe, Manabu ^b   Masuyama, Araki ^b   Nojima, Masatomo ^b   Sasaki, Takuma ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Anti angiogenic effect; Antitumor effect; Cyclic peroxide; Ozonide

Indexed keywords

1 PHENYL 1,4 EPOXY 1H,4H NAPHTHO[1,8 DE][1,2]DIOXEPIN; 1,4 EPOXY 1H,4H NAPHTHO[1,8 DE][1,2]DIOXEPIN; ANGIOGENESIS INHIBITOR; CATHEPSIN B; CYCLIC PEROXIDE; OZONIDE DERIVATIVE; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHICK EMBRYO; CHORIOALLANTOIS; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION;

AIR SACS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CATHEPSIN B; CHICK EMBRYO; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; NAPHTHALENES; NEOVASCULARIZATION, PATHOLOGIC; OXEPINS; RIBONUCLEASE, PANCREATIC; RNA, MESSENGER; SARCOMA; UMBILICAL VEINS; URINARY PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037054931     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10469     Document Type: Article

References (48)

1. Angiogenesis
2. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
3. Angiogenesis in cancer and other diseases
4. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial
5. Ongoing trials with matrix metalloproteinase inhibitors
6. Marimastat trial results
7. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
8. Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer
9. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
10. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2
11. Metalloproteases and urokinase in angiogenesis and tumor progression
12. Inhibition of endothelial cell proliferation and tumor-induced angiogenesis by pentoxifylline
13. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride
14. Antimetastatic effect of amiloride in an animal tumour model
15. Antimetastatic and antitumor effects of 2,4-diamino-6-(pyridine-4-yl)-1,3,5-triazine (4PyDAT) on the high lung metastatic colon 26 tumor in mice
16. TAC-101 (4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid) inhibits spontaneous mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma
17. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator
18. A diaminoantraquinone inhibitor of angiogenesis
19. Ozonolysis of acenaphthylene and 1-substituted acenaphthylenes
20. Ring-chain tauomerization. Part V. α-aroyl- and 8-acyl-1-naphthoic acids
21. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing
22. A highly sensitive chromogenic microtiter plate assay for plasminogen activators which quantitatively discriminates between the urokinase and tissue-type activators
23. A highly potent antiangiogenic activity of retinoids
24. Inhibition of angiogenesis by vitamin D3 analogues
25. Cathepsin B, cathepsin H, and cathepsin L
26. Cathepsin C: An allosteric enzyme
27. Human cathepsin H
28. Cathepsin L. A new proteinase from rat-liver lysosomes
29. Relationship between expression of plasminogen activator system and metastatic ability in human cancers
30. Effects of cytogenin, a novel microbial product, on embryonic and tumor cell-induced angiogenic responses in vivo
31. Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: Anti-angiogenic effect on HPV-harboring tumor-cell lines
32. Novel epoxysuccinyl peptides. A selective inhibitor of cathepsin B, in vivo
33. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA)
34. Cathepsin B activity in B16 melanoma cells: A possible marker for metastatic potential
35. Cathepsin B and its endogenous inhibitors: The role in tumor malignancy
36. Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases
37. Tumor progression and angiogenesis: Cathepsin B & Co
38. Secreted cathepsin L generates endostatin from collagen XVIII
39. Generation and degradation of human endostatin proteins by various proteinases
40. Immuno-detection of cathepsins B and L present in and secreted from human pre-malignant and malignant colorectal tumour cell lines
41. The role of cathepsin L in malignant transformation
42. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
43. Inhibition of tumour cell invasion by protease inhibitors: Correlation with the protease profile
44. Cysteine proteinases and their endogenous inhibitors: Target proteins for prognosis, diagnosis and therapy in cancer
45. Cathepsin B to cysteine proteinase inhibitor balance in metastatic cell subpopulations isolated from murine tumors
46. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity
47. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice
48. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways